Biotech

0 325
Biohaven Pharmaceutical Holding Co Ltd BHVN Stock News

Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) is having a relatively strong day in the market today after announcing that it has received Fast Track Designation. Of course, this led to excitement among investors, pushing the stock toward the top. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (12:07), BHVN is trading at $21.81 per share after a gain of $0.22 per share or 1.02% thus far today.





BHVN Gains On Fast Track Designation

As mentioned above, Biohaven Pharmaceutical Holding Company is having a strong day in the market today after announcing the the United States Food and Drug Administration has granted Fast Track Designation on a key product candidate. The candidate is trigriluzole (BHV-4157). The treatment is being studied for Spinocerebellar Ataxia (SCA). Previously, the treatment has received Orphan Drug Disignation from the FDA. Currently, the treatment is in the midst of a Phase 2/3 clinical trial with topline results expected to come down the line in 2018. In a statement, Vlad Coric, M.D., CEO at BHVN, had the following to offer…




This Fast Track Designation from the FDA recognizes the high unmet medical need in patients with SCA…. Fast track designation will help facilitate Biohaven’s development of trigriluzole, and potentially expedite future regulatory review of trigriluzole for patients with SCA.”

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on BHVN. In particular, we’re interested in following the company’s ongoing work with regard to trigriluzole and are excited for the results from the ongoing trial. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 1131
Valeant Pharmaceuticals Intl Inc VRX Stock News

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) had an incredible week in the market last week, and those gains are being followed up by yet another strong day in the market today. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (11:50), VRX is trading at $14.05 per share after a gain of $0.46 per share (3.39%) thus far today.





3 Reasons VRX Is Headed Up

As mentioned above, Valeant Pharmaceuticals is having yet another strong day in the market today after a strong performance throughout last week. So, why is it that the stock is headed up? Well, I can think of 3 reasons off of the top of my head…




Reason #1: Improving Revenue Outlook

Ever since the Philidor scandal caused VRX to cut off its largest customer and take a dive, revenue has been a bit of a concern. However, it seems as though revenue is starting to stabilize, and the company is expecting to start seeing growth. In fact, the company raised its Non-GAAP EBITDA expectations from between $3.55 billion and $3.7 billion to between $3.6 billion and $3.75 billion. The increased expectations are the result of stabilizing data in dermatology, growth in Asia, and staff changes at Salix.

Reason #2: Coming Product Launch

The next reason that VRX investors seem to be so excited has to do with a coming product launch. The company will soon be launching SILIQ. In fact, this is expected to take place during the current quarter. With a sales force of around 150 supporting the sale of the product, it is expected that SILIQ will soon be a strong source of revenue for the company.

Reason #3: An Impressive Pipeline

Valeant Pharmaceuticals already has several products on the market right now. However, their innovation hasn’t stopped. In fact, the company has several products in its pipeline at the moment. Those treatments include but are not limited to:

  • Latanoprostene – This treatment was designed for the treatment of Glaucoma and is expected to launch this year.
  • Stellaris® Elite – This is a cataract and retinal surgery platform developed by VRX which is expected to launch this year.
  • Vitesse (TM) – a hypersonic vitrectomy surgical device. It is expected that this will be submitted this year.
  • Next Generation Thermage® – An aesthetics devise for addressing fine lines and wrinkles, which VRX is expected to submit this year.

To view the full VRX pipeline, click here! Trust me, it’s well worth the click!

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

Final Thoughts

At the end of the day, VRX is starting to make an incredibly compelling recovery. While legal concerns surrounding the Philidor scandal are still there, it seems as though those have already been priced into the stock. As a result, investors are starting to focus on the company’s ability to grow. While there definitely is some risk involved here, the opportunity for gains could be massive. Nonetheless, we’ll continue to follow Valeant closely and bring you news as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 420
EXACT Sciences Corporation EXAS Stock News

EXACT Sciences Corporation (NASDAQ: EXAS) is off to an overwhelmingly rough day in the market today, and for good reason. Citron released a sell-side report on the stock, leading to concerns among investors and sending the stock tumbling downward. Of course, our partners at Trade Ideas were the first to alert us to the declines. At the moment (11:02), EXAS is trading at $31.77 per share after a loss of $2.00 per share or 5.92% thus far today.





EXAS Falls On Citron Report

As mentioned above, EXACT Sciences is off to an overwhelmingly rough start to the trading session today after Citron released a short report on the stock. In the report, Citron says that the company is making a business out of pushing a cancer test, known as Cologuard, to the public that is inferior by their own admission. As a result, the company is losing money in the process. In the first few paragraphs of the report, you can get the gist. Here’s what they had to say…




EXACT Sciences (NASDAQ: EXAS) pushes a cancer test (Cologuard) to the public, inferior by its own admission, and loses money doing it. That is why this $4 billion company is mainly owned by passive investing ETFs and other healthcare baskets.

More importantly, as Citron will expose, the key metrics not disclosed by EXACT sciences are getting worse, while Medicare pricing inefficiencies end next January and investors will be left with a decaying asset with no terminal value.

This stock is a poster child for what goes wrong when Wall Street gets ahold of a health care concept with no discrimination for whether its a good or bad medicine.”

To read the full Citron report on EXAS, click here.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on EXAS. In particular, we’re interested in following to see how the company responds to the short side report. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 1337
Novavax, Inc. NVAX Stock News

Novavax, Inc. (NASDAQ: NVAX) is off to an incredibly strong day in the market today, and for good reason. It has to do with yet another Ebola outbreak. While the outbreak is bad news for many, it’s great news for the company and its investors, who are excitedly pushing the stock toward the top. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:54), NVAX is trading at $1.12 per share after a gain of $0.12 per share (12.00%) thus far today.





NVAX Gains As More Die From Ebola

As mentioned above, Novavax is having a strong day in the market today as news of an Ebola outbreak hit yesterday. According to the World Health Organization, 3 people have died from the outbreak, which is taking place in a remote northern region of the Democratic Republic of Congo. Health officials are currently finding their way to the Central African country as a rising number of suspected cases are coming down the wire.




Of course, any outbreak of a serious health threat is bad news overall. However, for NVAX, the news is proving to be positive. After all, the company is working to perfect a vaccine for the condition. At the moment, all data surrounding the vaccine is proving to be overwhelmingly positive. So, there’s good reason for the gains that we’re seeing today.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on NVAX. In particular, we’re interested in following the company’s ongoing work with regard to Ebola, as well as the current outbreak taking place in the Democratic Republic of Congo. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 458
Ionis Pharmaceuticals Inc IONS Stock News

Ionis Pharmaceuticals Inc (NASDAQ: IONS) is having an incredibly rough start to the trading session today, and for good reason. The company released data from a key clinical trial, and while the data seemed positive at first, side effects proved to be a source of fear for investors. As a result, the stock is taking a bit of a dive, which prompted our partners at Trade Ideas to alert us to the declines. Currently (9:35), IONS is trading at $43.17 per share after a loss of $3.91 per share or 8.31% thus far today.





IONS Falls Hard On Clinical Data

As mentioned above, Ionis Pharmaceuticals is having a rough start to the trading session today after releasing results from a Phase 3 clinical trial. The trial, titled NEURO-TTR, was designed to assess inotersen for the treatment of inherited disorder familial amyloid polyneuropathy. While the study did indeed meet both the primary efficacy endpoints, side effects proved to be a major concern.

Unfortunately, three of the patients involved in the IONS trial developed thrombocytopenia, the technical term for low blood platelets. While two of the three patients recovered from the condition, one of the patients passed away due to an intracranial hemorrhage. Also, another patient was forced to discontinue treatment as a result of non-serious thrombocytopenia.




However, thrombocytopenia didn’t prove to be the only major side effect associated with the treatment. Unfortunately 4 more patients were forced to stop the treatment due to kidney events, one patient had to stop as a result of renal observation, one stopped treatment from chronic renal insufficiency, and two had to stop due to meeting a predefined renal stopping rule according to the release by IONS.

While the efficacy data proved to be overwhelmingly positive, Ionis Pharmaceuticals said that it is indeed working to continue the assessment of safety data. Unfortunately, even with great efficacy data, an unsafe drug is an unsafe drug my friends.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on IONS. In particular, we’re interested to see what the evaluation of safety data brings to the table. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 1036
Pernix Therapeutics Holdings PTX Stock News

Pernix Therapeutics Holdings (NASDAQ: PTX) is having a relatively strong start to the trading session in the pre-market hours today, and for good reason. Notes from Nobby Paul were released today, suggesting that a sale of the company is either under way or likely to take place very soon. Of course, this led to excitement among investors, prompting gains in the value of the stock and causing our partners at Trade Ideas to alert us to the movement. At the moment (9:02), PTX is trading at $5.97 per share after a gain of $0.12 per share (2.05%) thus far today.





A Strong Argument For A PTX Acquisition Is Forming

As mentioned above, Pernix Therapeutics is having a strong start in the trading session today after Nobby Paul published notes with regard to the company. In these notes, the clear expectation is that PTX will be acquired. Here are some of the strongest key points made in the notes that suggest that the company is going to be sold:




  • PTX hired Ken Pina in January. In the notes, Nobby Paul points out that “this guy is corporate governance and needed for the sale process.”
  • Zohydro litigation is resolved. However, that resolution with GSK gives GSK the right to review the sales process and bids; on top of that GSK also has the right to bid on the company.
  • It is also stated that Q4 earnings from Pernix Therapeutics point to a sale. In fact, Nobby Paul says that the company dumped all of the poor results they could fit into the 2016 report, pointing out that while this made the year 2016 look horrible, it sets the balance sheet up nicely for 2017.

I’ve Been Making This Argument Since Sedor Took The Position

The bottom line here, everyone, is that Nobby Paul isn’t likely wrong about PTX. In fact, he makes an incredibly compelling argument in his notes, which are available in full here. Nonetheless, the truth of the matter is that he wasn’t the first to say that the company is going up for sale soon. Several experts have pointed to this.

In fact, quite a while ago, when Sedor took the position as the CEO of the company, many, including myself, pointed to his record for coming in, setting companies up for sales, selling at a premium and returning value to shareholders. While this process does take time, there’s no doubt that Sedor isn’t likely to disappoint with PTX.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on PTX. In particular, we’re interested in following the company through continuous changes made by Sedor that seem to be setting the company up for a sale. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 1566
MannKind Corporation MNKD Stock News

MannKind Corporation (NASDAQ: MNKD) is having an incredibly rough time in the pre-market hours this morning, and for good reason. After reporting earnings, investor fears are starting to pick up yet again. However, that doesn’t seem to be a concern to billionaire investor David Shaw. So, what’s the deal here? Why is Shaw so interested in MNKD?





David Shaw’s DE Shaw Hedge Fund Is A Big Player In MNKD

As mentioned above, David Shaw has quite a bit of interest in MannKind. In fact, in his most recent SEC filing, Shaw increased his holding in the company by 347%. Today, DE Shaw owns 5,275,095 shares of the company, and at the current (8:29) price of $1.06 per share, that works out to be $5.5916 million in investing dollars in the company.




There’s No Doubt That Shaw Is Taking A Risk Here

The reality is that any time you make an investment, no matter how large or how small, you’re taking on some risk. However, in this case, David Shaw seems to have an incredibly high risk tolerance when it comes to MNKD. The truth is that when we dig into the numbers here, the risks become overwhelmingly clear.

Recently, MNKD released its earnings for the first quarter. In the report, investors learned that the company generated a total of $3 million in revenue in that quarter. However, less than half of that total, $1.2 million to be exact, came from the sale of the company’s flagship treatment, Afrezza. In fact, most of the company’s revenue came from selling off its bulk supply of insulin. Unfortunately, Afrezza simply isn’t selling as the company hoped. So, they are being forced to sell off their bulk supplies in an effort to get their hands on what little cash may be available to them.

David Shaw Doesn’t Seem To Mind

While the fact that MannKind can’t seem to get Afrezza sales above the 300-per-week mark, leading to poor earnings, David Shaw doesn’t seem to mind here. We’ve seen no evidence that he has sold or is planning to sell any of his position in the company. So, where’s the rub?  What is it that has Shaw hanging on so tightly?

Well, the truth is that I haven’t had an opportunity to speak with Shaw in order to get the answer right from him. Nonetheless, I do have a theory, and thinking about the possibilities here, it may be a good reason to hold on.

While MNKD can’t seem to get sales running, the company is a prime candidate for a takeover. At the moment, they are struggling financially in a big way. So, if another company wanted to take them over, now would be a great time, as they would likely have to pay less of a premium to do so. Nonetheless, Afrezza could be an incredibly profitable product. So, my theory is that Shaw is hanging on in order to reap the rewards of a potential sale coming down the line based on a competitor’s interest in owning the rights to the world’s first inhaled insulin.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on MNKD. In particular, we’re interested in following the company to see if any takeover interest starts to be seen. However, there’s also another silver lining. One Drop | Chrome recently made it to Amazon as a Prime product. The relationship between One Drop and MannKind could mean that this will result in stronger Afrezza sales. So, we’ll be watching the action there as well. We’ll continue to follow the story and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Athersys ATHX Stock News

Okay, Soulstring Nation, we are now delivering on 23 of the last 24 stocks featured in my weekly opine. Coming off last week’s massive 24% increase in Biohaven (BHVN), this week’s stock may offer just as much firepower as BHVN, and it’s certainly time that the market appreciates the value of this innovative and fast developing company. Today however, we’re going to focus on yet another incredible opportunity.

You Must Be A Subscriber To View This Content. Subscribe Here or Login Here

Premium Content!

You must be logged in to view this content. To see subscription plans, click here.

Disclosure: This article was written by Kenny Soulstring, and it reflects my own opinions and unique articulation. This article is not intended to offer investing advice, guarantee 100% accurate predictions or to be interpreted as providing a personal recommendation. What I can guarantee, though, is accurate research, thoughtful analysis and an enthusiasm about any stock that I cover.

I wrote this article myself and it includes my own research and expresses my own opinions. I am not receiving compensation for it (other than from CNA Finance). I have no business relationship with any company whose stock is mentioned in this article. I have no position in any stock mentioned, but may initiate a long position in ATHX within the next 72 hours. Past performance may not be indicative of future results. Therefore, no current or prospective client or subscriber should assume that the future performance of any specific investment, investment strategy (including the investments and/or investment strategies recommended and/or purchased by CNA Finance, Inc., it’s employees, or its affiliates), or product made reference to directly or indirectly on this website, or indirectly via link to any unaffiliated third-party website, will be profitable or equal to corresponding indicated performance levels.

Different types of investments involve varying degrees of risk, and there can be no assurance that any specific investment will either be suitable or profitable for a client’s investment portfolio.

Historical performance results for investment indexes and/or categories generally do not reflect the deduction of transaction and/or custodial charges or the deduction of an investment management fee, the incurrence of which would have the effect of decreasing historical performance results.

Material represented is believed to be from reliable sources and we make no representations as to its accuracy or completeness.

Biohaven Pharmaceuticals Holding Co Ltd BHVN Stock News

Biohaven Pharmaceuticals Holding Co Ltd (NYSE: BHVN)

Biohaven (BHVN) today announced that the company has officially closed its IPO, raising $193.5 million before deducting underwriting discounts, fees, and commissions. As a result of the full exercise of underwriters options, the total public offering size was 11,385,000 shares of common stock.

BHVN Has Momentum





BHVN was a featured stock of the week by Kenny Soulstring on Monday, where he introduced CNA Finance followers and subscribers to the company at $17.00 per share. Since his introduction, BHVN has traded higher by over 27% at the time of this publication. According to Soulstring’s article, BHVN has further to run, banking on the company’s pending phase III trials targeting chronic migraine and ALS.

BHVN is advancing BHV-3000 and BHV-3500 to target and treat chronic migraine through its CGRP platform. The company is also developing BHV-4157 in a potentially pivotal Phase IIb/III trial to assess efficacy and safety in treating patients with Hereditary spinal ataxia (SCA).

Trading BHVN Through PTGEF




Investors have been taking advantage of the leverage through Portage Biotech (PTGEF), who has a 28% ownership stake in BHVN. PTGEF, which trades at .38 cents (10:02est) is one of the largest shareholders in BHVN and is developing additional opportunities for its shareholders through its ownership interests in Sentien, EyGen and Portage Pharmaceuticals.

Since the lead into the IPO, PTGEF has enjoyed share price traction to the upside, trading higher by over 40% since the news of the pending BHVN IPO was announced. Since the BHVN offering, PTGEF stock has risen by over 15%.

Taking a look at BHVN either as a straight-up investment or through PTGEF may prove to be a wise decision. Each stock, at current levels, may prove undervalued and both are actively developing and working hard to deliver novel drugs to market. The investment in either brings with it a platform to develop innovative medicines that are looking to serve unmet medical needs.

Disclosure: This article was written by Kenny Soulstring, and it reflects my own opinions and unique articulation. This article is not intended to offer investing advice, guarantee 100% accurate predictions or to be interpreted as providing a personal recommendation. What I can guarantee, though, is accurate research, thoughtful analysis and an enthusiasm about any stock that I cover.

While I seek to uncover emerging companies that I feel have true value and potential, it’s important that investors assign an appropriate time horizon to each of their investments, understanding that emerging companies need time to mature.

I wrote this article myself and it includes my own research and expresses my own opinions. I am not receiving compensation for it (other than from CNA Finance). I have no business relationship with any company whose stock is mentioned in this article.

Additional Disclosure: I am long PTGEF and may purchase additional shares within the next 72 hours.I have no position in BHVN.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 1877
Rexahn Pharmaceuticals, Inc. RNN Stock News

Rexahn Pharmaceuticals, Inc. (NYSEMKT: RNN) is having an overwhelmingly strong day in the market today. While no new news has been released today, a quick look on StockTwits tells the whole story. At the end of the day, investors are excited, as the company’s flagship candidate is quickly making its way to its next data release. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (9:54), RNN is trading at $4.49 per share after a gain of $0.52 per share (13.10%) thus far today.





RNN Flagship Candidate Moves Along Swimmingly

As mentioned above, investors are overwhelmingly excited about Rexahn Pharmaceuticals today, sending the stock skyward. While we didn’t find anything new in our search for reasons for the movement, we were able to find something. A quick search on StockTwits showed that investors seem to be most excited about the company’s flagship candidate, and for good reason.




You see, on May 8th, investors were given a press release surrounding RX-3117. This is the company’s prime candidate in the treatment of various cancers, including but not limited to metastatic bladder cancer. While the treatment has been through the Phase IIa clinical trial, the data has not yet been released. However, investors don’t have to wait much longer. According to the PR that was released on the 8th, this data will be presented at the American Society of Clinical Oncology 2017 Annual Meeting. At the meeting, RNN will be providing data on Sunday, June 4th, between the hours of 8:00 am and 11:30 am CDT.

This is overwhelmingly positive news. After all, if the data wasn’t positive, the presentation would not have been chosen by the ASCO for release at their meeting. As a result, it’s easy to come to the conclusion that on Sunday, June 4th, 2017, investors are going to receive some overwhelmingly positive news.

Stop wasting your time! Find winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on RNN. In particular, we’re interested in following the ongoing development of RX-3117 and overwhelmingly excited to see the results of the Phase IIa clinical trial. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 5133
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...